Breaking Advances
Cancer Res September 15 2010 70 (18) 7015-7016; DOI:10.1158/0008-5472.CAN-70-18-BA
Findings define a biopsy marker that may predict the type of therapy most likely to cure individual patients of invasive bladder cancer.
Study illustrates how cytotoxic nanoparticle therapies can incorporate an approved MRI contrast agent for superior noninvasive imaging in vivo, easing analysis of preclinical and clinical pharmacology.
Metastasis promoted by macrophages may be assisted by the sympathetic nervous system and thus blocked by drugs that antagonize adrenergic signaling.
Quantitative noninvasive imaging of lymphatic flow will greatly assist the study of experimental cancer drugs being developed to target lymphatics, as well as the ability to image lymphedema and sentinel lymph nodes in cancer.
Findings suggest that osteoclast-preserving therapies may help prevent or delay metastatic development in osteosarcoma.
Stromal hyaluronan serves as a microenvironmental signal for recruitment of tumor-associated macrophages, which are key cells involved in tumor neovascularization.
Clinical findings support the concept that the use of chemotherapy before a cancer vaccine can promote renewal of tumor-reactive T cells and extend survival.
Findings suggest a mechanism through which caveolin-1 can mediate antimetastatic effects in melanoma.
Genotoxic and cell-stressing chemicals sensitize tumor cells to MHC-independent missing-self recognition by NK cells.
Cooperation between K-ras activation and PTEN loss during pancreatic carcinogenesis occurs at the early stage of acinar-to-ductal metaplasia.
Findings suggest applications of a neutrophil protease inhibitor that can attack breast cancer cells without affecting normal proliferating cells.
Findings contribute to growing evidence that modification of hnRNP A2/B1 expression exerts a major impact on the proliferation and invasive capacity of lung cancer cells.
Findings offer preclinical genetic proof that an Mdm2 relative is a critical regulator of p53 and thus a valid therapeutic target to activate p53 in tumors.
Results define a regulatory mechanism that supports contributions of the p53-related protein p73 as a key mediator of the response to platinum chemotherapy in certain ovarian carcinomas.
Results define a key intersection between cell cycle control and estrogen receptor signaling that has implications for breast cancer progression.
Findings define a mechanism by which a DNA damage-induced microRNA controls a nodal regulator of DNA damage signaling.
Individuals with substantial exposure to radiation who are diagnosed with a first primary cancer should be carefully screened for second primary cancers, particularly those that are radiation sensitive.
Findings define a genetic marker elevating susceptibility to HPV-associated oral cancers, particularly in never smokers, never drinkers, and oropharyngeal cancer patients.
Ectopic expression of a common TLR adapter signaling protein can exert all the benefits of TLR signaling to antitumor immunity.
Study offers the first definition and comparison of acquired resistance mechanisms for IGF-1R targeted therapies.
Findings demonstrate that direct activation of procaspase-3 by a small molecule can be well tolerated and efficacious as an anticancer strategy.
Mechanistic studies reveal the basis for a cancer-selective cell death pathway that might be exploited to improve the treatment of multiple myeloma.
Findings offer preclinical proof of concept for a highly effective combinatorial therapy for colorectal tumors which targets three key oncoproteins.
Findings strengthen the emerging evidence that alterations in RNA splicing occuring widely in cancer cells functionally contributes to malignant development.
Findings establish a strategy to follow and target bone marrow-derived endothelial progenitor cells that are vital for tumor angiogenesis.
Findings identify the Ang-4/Tie-2 receptor axis as an attractive therapeutic target to treat aggressive brain cancers.
Cancer-associated fibroblasts may exert their robust contributions to malignant phenotype by promoting the tumorigenic potential of cancer stem cells.
Findings suggest that mutationally activated and ligand activated forms of growth factor receptors regulate distinct transcription programs that differentially affect motility, stress response, and stem cell properties.
Simultaneous MRI and fluorescent imaging of tumors can be used to noninvasively monitor metastasis and response to cell or gene-based therapies with the use of an engineered lentiviral system.
Results reveal a previously undefined linkage in BCR-ABL effector signaling that is essential to drive transformation of hematopoietic progenitor cells.
A survival pathway in chronic lymphocytic leukemia responding to antigenic and stromal support might be targeted by disrupting an Akt pathway mediating this support.